Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Secoisolariciresinol diglucoside (SDG) is a plant lignan found primarily in flaxseed. There is scientific evidence suggesting potential benefits of SDG for prostate health, though the evidence is not yet robust or conclusive. SDG is metabolized by gut bacteria into mammalian lignans, specifically enterolactone and enterodiol, which have demonstrated weak phytoestrogenic activity. Some in vitro and animal studies suggest these metabolites can inhibit the growth of prostate cancer cells by modulating hormone metabolism, reducing oxidative stress, and exerting anti-inflammatory effects. Several observational studies have found an association between higher dietary intake of flaxseed lignans and reduced risk of prostate cancer, but human clinical trials are limited and results are mixed. One small pilot study found that flaxseed supplementation reduced tumor proliferation rates in men with prostate cancer, but did not isolate SDG as the active component. Overall, while preclinical data and some epidemiological observations support a possible benefit of SDG for prostate health, large, well-designed clinical trials are needed to establish efficacy and optimal dosing. Its use for prostate health is thus supported by preliminary scientific evidence but not yet by strong clinical data.

More about secoisolariciresinol diglucoside
More about Prostate

Other ingredients that support Prostate

Other body systems supported by secoisolariciresinol diglucoside

Products containing secoisolariciresinol diglucoside

Metagenics Axis Endo™ Mango